Letters
Rosiglitazone saga
Demonisation of rosiglitazone
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2571 (Published 21 April 2011) Cite this as: BMJ 2011;342:d2571- Vernon J Heazlewood, senior staff specialist
- 1Queensland Health Metro North HSD, Caboolture Hospital, Caboolture, QLD 4510, Australia
- vtheazle{at}bigpond.net.au
Loke and colleagues consider the idea that pioglitazone yields cardiovascular benefits, but readily dismiss it.1 This is an equally plausible explanation of the analysis, however, given that it compares pioglitazone and rosiglitazone rather than placebo or control treatment. There is moderate …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.